SCHEMBL6175144

SCHEMBL6175144

CC1(Cc2ccncc2NC(=O)Oc2ccccc2)NC(=O)N(c2ccc(SC(F)(F)F)cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 15/20 0.39
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NTRK1 P04629 1/20 0.34
KDM4C Q9H3R0 2/20 0.33
KDM5A P29375 1/20 0.33
KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173492 0.88 KCNK2 (0.41) IGF1RALDH1A1CYP3A4GAACYP2C9
SCHEMBL6174742 0.87 IGF1R (0.40) IGF1RALDH1A1CYP3A4GAACYP2C9
SCHEMBL6171771 0.87 IGF1R (0.41) IGF1RNTRK1KDM4C
SCHEMBL6171502 0.86 IGF1R (0.39) IGF1RALDH1A1CYP3A4GAACYP2C9
SCHEMBL6173999 0.84 IGF1R (0.40) IGF1RALDH1A1GAA
SCHEMBL6174077 0.84 CYP3A4 (0.49) IGF1RALDH1A1CYP3A4GAACYP2C9
SCHEMBL6172175 0.83 IGF1R (0.37) IGF1RALDH1A1CYP3A4GAACYP2C9
SCHEMBL2932168 0.83 IGF1R (0.56) IGF1R
SCHEMBL6171072 0.83 IGF1R (0.42) IGF1RALDH1A1NTRK1KDM4C
SCHEMBL6173746 0.82 LMNA (0.42) IGF1RALDH1A1CYP3A4GAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed